Evaluation of proposals for new products on the National Blood Product List (2013)

Evaluation of proposals for new products on the National Blood Product List (2013)

The National Blood Authority (NBA) engaged HealthConsult to provide expert health technology assessment, analytical and advisory services to assist with evaluations of proposals to include new products under the funding and supply arrangements of Schedule 4 of the National Blood Agreement. The projects involve a review of the evidence for safety, effectiveness and cost-effectiveness of the blood product, together with an analysis of the financial implications for the national blood budget and government health budgets.